Cancer cells are more resistant to complement-mediated lysis and use this attribute to set up a locally immunosuppressive environment. However, new findings suggest that tumor-driven complement activation can also provide the tumor a growth advantage.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer
Nature Communications Open Access 02 October 2022
-
High complement protein C1q levels in pulmonary fibrosis and non-small cell lung cancer associated with poor prognosis
BMC Cancer Open Access 25 January 2022
-
C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation
Nature Communications Open Access 01 February 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nauts, H.C. & McLaren, J.R. Adv. Exp. Med. Biol. 267, 483–500 (1990).
Davis, I.D. et al. J. Leukoc. Biol. 73, 3–29 (2003).
Markiewski, M.M. et al. Nat. Immunol. 9, 1225–1235 (2008).
Dunn, G.P. et al. Annu. Rev. Immunol. 22, 329–360 (2004).
Sica, A. & Bronte, V. J. Clin. Invest. 117, 1155–1166 (2007).
Allavena, P. et al. Immunol. Rev. 222, 155–161 (2008).
Dechant, M. et al. Cancer Res. 68, 4998–5003 (2008).
Clynes, R.A. et al. Nat. Med. 6, 443–446 (2000).
Stavenhagen, J.B. et al. Cancer Res. 67, 8882–8890 (2007).
Watson, N.F. et al. Cancer Immunol. Immunother. 55, 973–980 (2006).
Zell, C. et al. Clin. Exp. Immunol. 150, 576–584 (2007).
Varela, J.C. et al. Cancer Res. 68, 6734–6742 (2008).
Kemper, C. & Atkinson, J.P. Nat. Rev. Immunol. 7, 9–18 (2007).
Manderson, A.P. et al. J. Exp. Med. 194, 747–756 (2001).
Wu, X. et al. J. Immunol. 181, 2732–2740 (2008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Loveland, B., Cebon, J. Cancer exploiting complement: a clue or an exception?. Nat Immunol 9, 1205–1206 (2008). https://doi.org/10.1038/ni1108-1205
Issue Date:
DOI: https://doi.org/10.1038/ni1108-1205
This article is cited by
-
High complement protein C1q levels in pulmonary fibrosis and non-small cell lung cancer associated with poor prognosis
BMC Cancer (2022)
-
Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer
Nature Communications (2022)
-
C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation
Nature Communications (2016)
-
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
British Journal of Cancer (2010)